OBJECTIVE: In the studies carried out to date, the cost of chronic obstructive pulmonary disease (COPD) may have been overestimated due to the inclusion of previously diagnosed patients seeking medical attention for their symptoms. As a result, the severity of the cases included in these studies may have been greater than in an unselected sample of the general population. The aim of the present study was to estimate the direct cost of COPD on the basis of a representative sample of the overall Spanish population between 40 and 69 years of age (from the IBERPOC study). METHOD: The cost was evaluated retrospectively by means of a questionnaire completed by the 363 patients with COPD from the IBERPOC study with questions referring to the previous year. Standardized spirometry was performed on all the patients by a pneumologist in each of the 7 geographical areas in which the study was carried out. RESULTS: Hospitalization accounted for the greatest expenditure (41% of total), followed by drug therapy (37%). The cost was euro;98.39 per patient, and euro;909.50 per previously diagnosed patient. The cost per person of severe COPD was more than 3 times that of moderate COPD and more than 7 times that of mild COPD. The estimated annual cost of COPD in Spain was euro;238.82 million (for 1997). CONCLUSION: The present study, which was the first to estimate the cost of COPD in a representative sample of the general population, found the cost to be lower than in studies analyzing samples of patients with previous diagnoses of COPD. The cost distribution is not in line with recommended health care practices, underlining the need to optimize resources used to monitor and treat the disease, with an emphasis on early diagnosis.
OBJECTIVE: In the studies carried out to date, the cost of chronic obstructive pulmonary disease (COPD) may have been overestimated due to the inclusion of previously diagnosed patients seeking medical attention for their symptoms. As a result, the severity of the cases included in these studies may have been greater than in an unselected sample of the general population. The aim of the present study was to estimate the direct cost of COPD on the basis of a representative sample of the overall Spanish population between 40 and 69 years of age (from the IBERPOC study). METHOD: The cost was evaluated retrospectively by means of a questionnaire completed by the 363 patients with COPD from the IBERPOC study with questions referring to the previous year. Standardized spirometry was performed on all the patients by a pneumologist in each of the 7 geographical areas in which the study was carried out. RESULTS: Hospitalization accounted for the greatest expenditure (41% of total), followed by drug therapy (37%). The cost was euro;98.39 per patient, and euro;909.50 per previously diagnosed patient. The cost per person of severe COPD was more than 3 times that of moderate COPD and more than 7 times that of mild COPD. The estimated annual cost of COPD in Spain was euro;238.82 million (for 1997). CONCLUSION: The present study, which was the first to estimate the cost of COPD in a representative sample of the general population, found the cost to be lower than in studies analyzing samples of patients with previous diagnoses of COPD. The cost distribution is not in line with recommended health care practices, underlining the need to optimize resources used to monitor and treat the disease, with an emphasis on early diagnosis.
Authors: Marc Miravitlles; Miriam Calle; Francisco Alvarez-Gutierrez; Elena Gobartt; Francisco López; Antonio Martín Journal: Qual Life Res Date: 2006-04 Impact factor: 4.147
Authors: Melanie Schroeder; Nicole Benjamin; Laura Atienza; Chandroday Biswas; Alan Martin; John D Whalen; José Luis Izquierdo Alonso; Juan Antonio Riesco Miranda; Juan José Soler-Cataluña; Alicia Huerta; Afisi S Ismaila Journal: Int J Chron Obstruct Pulmon Dis Date: 2020-07-10
Authors: David de la Rosa; Miguel-Angel Martínez-Garcia; Casilda Olveira; Rosa Girón; Luis Máiz; Concepción Prados Journal: Chron Respir Dis Date: 2016-07-07 Impact factor: 2.444
Authors: Ignasi Bolíbar; Vicente Plaza; Mariantònia Llauger; Ester Amado; Pedro A Antón; Ana Espinosa; Leandra Domínguez; Mar Fraga; Montserrat Freixas; Josep A de la Fuente; Iskra Liguerre; Casimira Medrano; Meritxell Peiro; Mariantònia Pou; Joaquin Sanchis; Ingrid Solanes; Carles Valero; Pepi Valverde Journal: BMC Public Health Date: 2009-02-24 Impact factor: 3.295
Authors: Yeon Jae Kim; Byung Ki Lee; Chi Young Jung; Young June Jeon; Dae Sung Hyun; Kyung Chan Kim; Sung Ken Yu; Hye Sook Choi; Won Hyuk Shin; Kwan Ho Lee Journal: Korean J Intern Med Date: 2012-11-27 Impact factor: 2.884
Authors: Javier de Miguel Diez; Pilar Carrasco Garrido; Marta García Carballo; Angel Gil de Miguel; Javier Rejas Gutierrez; José M Bellón Cano; Valentín Hernández Barrera; Rodrigo Jimenez García Journal: Int J Chron Obstruct Pulmon Dis Date: 2008